Drug evaluation: PTC-124--a potential treatment of cystic fibrosis and Duchenne muscular dystrophy.
about
Molecular and cell-based therapies for muscle degenerations: a road under constructionSMRT compounds correct nonsense mutations in primary immunodeficiency and other genetic modelsCystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectivesClinical and molecular characterization of a cohort of patients with novel nucleotide alterations of the Dystrophin gene detected by direct sequencingCFTR Modulators for the Treatment of Cystic Fibrosis.Targets for cystic fibrosis therapy: proteomic analysis and correction of mutant cystic fibrosis transmembrane conductance regulatorAminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophyA translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophyMolecular therapeutic strategies targeting Duchenne muscular dystrophyNovel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agentsMicroarray-based mutation detection in the dystrophin gene.Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease.Mesenchymal stem cells: emerging therapy for Duchenne muscular dystrophyRescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides.
P2860
Q24568176-9B133B7B-B412-4216-ACE8-D4730BC8428EQ27007538-9BD19002-C177-483A-8242-DE85D298B734Q28073063-9C7E5944-A85E-4132-A825-01B306AC3B44Q33843901-A7118510-B301-46F4-833B-2F21ECF87210Q33920366-C2A2F919-24EE-4BF5-B205-A1D3C6B4DEB9Q34082569-BB94A559-EB72-4396-A9A6-1CE7155988BBQ34409434-E102C40C-A5D3-4435-B9B0-E74B06C95922Q36151226-4BA255CB-18C4-4D18-93CA-8BE32B2D1B02Q36907560-23C45A3A-B07A-41DD-9F91-76CDA9D909E7Q36925191-B16FACD7-BB8F-495B-B4F1-0A7113B7D44CQ36952935-ABD78141-37DB-4174-82CF-5C61A4AE1C5AQ37280594-46B41E41-B53D-4421-877B-E174027E6414Q37560090-ADA6D9B6-DC71-4CDD-BC1A-EBFA1B4D2D1CQ39621228-1A63BDED-9722-46E0-864C-2E3320C91E03
P2860
Drug evaluation: PTC-124--a potential treatment of cystic fibrosis and Duchenne muscular dystrophy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Drug evaluation: PTC-124--a po ...... d Duchenne muscular dystrophy.
@ast
Drug evaluation: PTC-124--a po ...... d Duchenne muscular dystrophy.
@en
Drug evaluation: PTC-124--a po ...... d Duchenne muscular dystrophy.
@nl
type
label
Drug evaluation: PTC-124--a po ...... d Duchenne muscular dystrophy.
@ast
Drug evaluation: PTC-124--a po ...... d Duchenne muscular dystrophy.
@en
Drug evaluation: PTC-124--a po ...... d Duchenne muscular dystrophy.
@nl
prefLabel
Drug evaluation: PTC-124--a po ...... d Duchenne muscular dystrophy.
@ast
Drug evaluation: PTC-124--a po ...... d Duchenne muscular dystrophy.
@en
Drug evaluation: PTC-124--a po ...... d Duchenne muscular dystrophy.
@nl
P1476
Drug evaluation: PTC-124--a po ...... d Duchenne muscular dystrophy.
@en
P2093
Sherifa A Hamed
P304
P577
2006-11-01T00:00:00Z